Treatment of Adult Gliomas: A Current Update

키워드

참고문헌 (51)

1. Wen PY, "Malignant gliomas in adults", N Engl J Med, 359, pp.492~507 (2008)
2. 이주호, "The origin-of-cell harboring cancer-driving mutations in human glioblastoma", BMB Reports, 51(10), pp.481~483 (2018), 생화학분자생물학회
3. Lee JH, "Human glioblastoma arises from subventricular zone cells with low-level driver mutations", Nature, 560, pp.243~247 (2018)
4. Figarella-Branger D, "The 2021WHO classification of tumours of the central nervous system", Ann Pathol, 42, pp.367~382 (2022)
5. Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", N Engl J Med, 352, pp.987~996 (2005)
6. van den Bent MJ, "Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults : the EORTC 22845 randomised trial", Lancet, 366, pp.985~990 (2005)
7. Ostrom QT, "CBTRUS statistical report : primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016", Neuro Oncol, 21, pp.v1~v100 (2019)
8. Esteller M, "Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents", N Engl J Med, 343, pp.1350~1354 (2000)
9. Eckel-Passow JE, "Glioma groups based on 1p", 19q, IDH, and TERT promoter mutations in tumors, 2015, pp.372, 2499~2508
10. Stummer W, "Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma : a randomised controlled multicentre phase III trial", Lancet Oncol, 7, pp.392~401 (2006)
11. 김성민, "Intraoperative Neurophysiologic Monitoring: Basic Principles and Recent Update", Journal of Korean Medical Science, 28(9), pp.1261~1269 (2013), 대한의학회
12. Gulati S, "The risk of getting worse : surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma", World Neurosurg, 76, pp.572~579 (2011)
13. Sorensen von Essen H, "Development of a patient decision aid to support shared decision making for patients with recurrent high-grade glioma", Int J Environ Res Public Health, 19, pp.7396~ (2022)
14. Molinaro AM, "Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma", JAMA Oncol, 6, pp.495~503 (2020)
15. Grabowski MM, "Residual tumor volume versus extent of resection : predictors of survival after surgery for glioblastoma", J Neurosurg, 121, pp.1115~1123 (2014)
16. Roh TH, "Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area : a retrospective study", J Neurosurg, 132, pp.895~901 (2019)
17. Duffau H, "Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up", Acta Neurochir(Wien), 158, pp.51~58 (2016)
18. Ding X, "The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma : a multicenter retrospective study", J Neurooncol, 140, pp.591~603 (2018)
19. Yordanova YN, "Supratotal resection of diffuse gliomas-an overview of its multifaceted implications", Neurochirurgie, 63, pp.243~249 (2017)
20. Baumert BG, "Temozolomide chemotherapy versus radiotherapy in high-risk lowgrade glioma(EORTC 22033-26033) : a randomised, open-label, phase 3 intergroup study", Lancet Oncol, 17, pp.1521~1532 (2016)
21. Bell EH, "Comprehensive genomic analysis in NRG oncology", RTOG 9802 : a phase III trial of radiation versus radiation plus procarbazine, lomustine(CCNU), and vincristine in high-risk low-grade glioma, 2020, pp.38, 3407~3417
22. Karim AB, "A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma : European Organization for Research and Treatment of Cancer(EORTC)Study 22844", Int J Radiat Oncol Biol Phys, 36, pp.549~556 (1996)
23. Shaw E, "Prospective randomized trial of low-versus highdose radiation therapy in adults with supratentorial low-grade glioma : initial report of a North Central Cancer Treatment Group", Radiation Therapy Oncology Group, J Clin Oncol, pp.2002, 20[DOI]
24. Cairncross G, "Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma : long-term results of RTOG 9402", J Clin Oncol, 31, pp.337~343 (2013)
25. van den Bent MJ, "Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma : long-term follow-up of EORTC brain tumor group study 26951", J Clin Oncol, 31, pp.344~350 (2013)
26. Wick W, "Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide", Neuro Oncol, 18, pp.1529~1537 (2016)
27. Jaeckle KA, "CODEL : phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p", 19q codeleted oligodendroglioma. Analysis from the initial study design, 2021, pp.23, 457~467
28. van den Bent MJ, "Adjuvant and concurrent temozolomide for 1p", 19q non-co-deleted anaplastic glioma(CATNON; EORTC study 26053-22054) : second interim analysis of a randomised, open-label, phase 3 study, 2021, pp.22, 813~823
29. Louis DN, "The 2016 World Health Organization classification of tumors of the central nervous system : a summary", Acta Neuropathol, 131, pp.803~820 (2016)
30. Gilbert MR, "Dose-dense temozolomide for newly diagnosed glioblastoma : a randomized phase III clinical trial", J Clin Oncol, 31, pp.4085~4091 (2013)
31. Balana C, "A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma(GEINO 14-01)", Neuro Oncol, 22, pp.1851~1861 (2020)
32. Chinot OL, "Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma", N Engl J Med, 370, pp.709~722 (2014)
33. Gilbert MR, "A randomized trial of bevacizumab for newly diagnosed glioblastoma", N Engl J Med, 370, pp.699~708 (2014)
34. Cancer Genome Atlas Research Network, "Comprehensive genomic characterization defines human glioblastoma genes and core pathways", Nature, 455, pp.1061~1068 (2008)
35. Lassman A, "ACTR-21. A randomized, double-blind, placebo-controlled phase 3 trial of depatuxizumab mafodotin (ABT-414) in epidermal growth factor receptor (EGFR) amplified (AMP) newly diagnosed glioblastoma (nGBM)", Neuro Oncol, 21, pp.vi17~ (2019)
36. Van Den Bent M, "INTELLANCE 2", EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma, 2020, pp.22, 684~693
37. Weller M, "Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma(ACT IV) : a randomised, double-blind, international phase 3 trial", Lancet Oncol, 18, pp.1373~1385 (2017)
38. Souhami L, "Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme : report of Radiation Therapy Oncology Group 93-05 protocol", Int J Radiat Oncol Biol Phys, 60, pp.853~860 (2004)
39. MalouffTD, "Carbon ion radiotherapy in the treatment of gliomas : a review", J Neurooncol, 145, pp.191~199 (2019)
40. Keime-Guibert F, "Radiotherapy for glioblastoma in the elderly", N Engl J Med, 356, pp.1527~1535 (2007)
41. Roa W, "Abbreviated course of radiation therapy in older patients with glioblastoma multiforme : a prospective randomized clinical trial", J Clin Oncol, 22, pp.1583~1588 (2004)
42. Malmström A, "Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma : the Nordic randomised, phase 3 trial", Lancet Oncol, 13, pp.916~926 (2012)
43. Roa W, "International atomic energy agency randomized phase III study of radiation therapy in elderly and", or frail patients with newly diagnosed glioblastoma multiforme, 2015, pp.33, 4145~4150
44. Wick W, "Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly : the NOA-08 randomised, phase 3 trial", Lancet Oncol, 13, pp.707~715 (2012)
45. Wick A, "Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma", Neuro Oncol, 22, pp.1162~1172 (2020)
46. Wee CW, "Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort : is short-course radiotherapy enough or is it a matter of selection?", J Neurooncol, 148, pp.57~65 (2020)
47. Bradley S, "I could lose everything : understanding the cost of a brain tumor", J Neurooncol, 85, pp.329~338 (2007)
48. Weller M, "European Association for Neuro-Oncology(EANO)guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas", Lancet Oncol, 18, pp.e315~e329 (2017)
49. Pitter KL, "Corticosteroids compromise survival in glioblastoma", Brain, 139, pp.1458~1471 (2016)
50. van Breemen MS, "Efficacy of antiepileptic drugs in patients with gliomas and seizures", J Neurol, 256, pp.1519~1526 (2009)
51. Glantz MJ, "Practice parameter : anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standards subcommittee of the American Academy of Neurology", Neurology, 54, pp.1886~1893 (2000)

관련 논문AI추천